Drug Update 2021

Latest Developments in the Treatment of HS

Speaker: Dr. Raed Alhusayen

Q&A

Principals of Basic Care for Xerosis

A structured symptom- and evidence-based approach including a road map for diagnosis and treatment of xerosis cutis. The session aims to raise awareness in terms of prevention and early treatment of this condition and may thus improve quality of life and prevent potential sequelae.

Beyond Sunscreen and Retinoids: Will Patients Benefit From An Antioxidant Serum?

The antioxidant treatment choices are numerous leading to confusion in product claims for patients and for clinicians, with a paucity of clinical data. Do patients really benefit from the use of antioxidants? Is every antioxidant serum the same? What clinical scenarios will provide optimal clinical outcomes?

Objectives:

• Discuss the deleterious effects of free radicals on the skin and the aging process
• Review the existing literature of use of antioxidants in skincare, providing insight to the question whether antioxidant serums actually influence the way our skin ages.
• Discuss the importance of clinical data to support serum selection.

Topical Therapy for Psoriasis: Past, Present and Future

Objectives:

• Provide an overview of current topical treatment approaches for the management of PsO
• Discuss the challenges of managing psoriasis across the body using a case-based approach
• Present and review data on emerging therapeutic topical agents for the treatment of PsO

Summary:
This 30-minute session led by Dr. Melinda Gooderham and Dr. Chih-ho Hong will discuss the approach to managing psoriasis using today’s topical therapies, provide attendees with a framework for enhancing their understanding of the potential use of new topical therapies for the treatment of psoriasis by discussing emerging data and use patient cases to illustrate the present day challenges for Canadian clinicians in managing psoriasis.

Uncovering: Novel Agents, Key Data, and Patient Confidence in AD

This session is a dynamic and interactive program designed to uncover the clinical benefits of novel AD treatments, reveal key data for efficacy outcomes, and includes an interactive discussion on practical applications.

Objectives:

At the end of this program, participants will be able to:

1. Define the clinical benefits of novel therapies
2. Apply key data for effective outcomes with AD patients
3. Explain to patients the mechanism of effect of AD therapy to support body and emotional confidence

Colloidal Oatmeal: Clinical Research Explored

Objectives:

• Review the components and the multifaceted benefits of colloidal oatmeal and the research supporting its effect on the moisture barrier
• Recognize the skin benefits of colloidal oatmeal by assessing the clinical research in various populations/skin conditions such as eczema, skin of colour and xerosis

Taking the Long View in Disease Control in Atopic Dermatitis

Patients with AD truly experience a Multidimension disease Burden. This includes debilitating the burden of signs of AD but also the consequences of AD symptoms on overall Quality of life. Another challenge that AD Patients face is living with the unpredictability of the disease, not knowing when a flare could occur. Episodic management of AD may not address the overall disease burden. AD being a chronic disease, patients suffering from uncontrolled disease can benefit from long term management. This symposium will look at considerations for selecting an AD treatment option for long-term use, all while reviewing most recent Long term and Real World evidence data in the management of moderate to severe atopic dermatitis.

Objectives :

1. Understand the current concepts around Long-Term control of atopic dermatitis
2. Review considerations for selecting an AD treatment option for long-term use
3. Review recent long-term and RWE data for biologic therapy in atopic dermatitis

Emerging Oral Therapies for the Treatment of Moderate-to-Severe Psoriasis

This presentation will describe the unmet needs of patients with moderate-to-severe psoriasis and present the latest phase III trials data of emerging targeted oral options (TYK2 inhibitors). It will include interactivity, notably polling questions, a case study, and practical tips.

Objectives:

• Define the existing unmet needs for patients with moderate-to-severe psoriasis and discuss the potential role for emerging targeted oral options o Differentiate the mechanism of action of JAK inhibitors and TYK2 inhibitors
• Review the clinical relevance of the efficacy and safety data for TYK2 inhibitors
• Identify where TYK2 inhibitors fit in treating moderate-to-severe psoriasis

Treating moderate-to-severe plaque psoriasis to target: new and old concepts for topical and biologic therapies

Treat-to-target (T2T) refers to a clinical framework for managing chronic diseases that sets standards for assessing treatment goals and suggests treatment strategies if targets are not achieved. T2T recommendations in moderate-to-severe plaque psoriasis have been published by expert groups from around the world. In these, treatment target is usually defined by a single severity measure, targets vary between consensus groups, and there are few recommendations for modifying treatment if target is not achieved. In this symposium, we present a multi-dimensional, criteria-based, T2T model developed by Canadian dermatologists managing moderate-to-severe plaque psoriasis. Treatment modification strategies will be presented and discussed with a focus on optimizing or switching biologic treatments. As topical treatments as mainstays in managing psoriasis, their role within a T2T model will be discussed with consideration given to long-term data from recently published studies.

Objectives:

• Introduce a Canadian criteria-based model for treatment targets in plaque psoriasis.
• Review evidence supporting treatment strategies for when target is not achieved, with a focus on switching biologics.
• Consider a treat-to-target approach in the early management of plaque psoriasis and critically appraise new clinical data on the long-term management of plaque psoriasis using topical treatments

Advances in Acne Vulgaris: Updates in topical retinoid therapy

Objectives:

• Describe new developments in topical retinoid treatments for acne vulgaris
• Recognize key considerations around vehicles for topical treatments in dermatology
• Integrate data on safety and efficacy of retinoids into the treatment of acne vulgaris in day-to-day practice

Summary description of the session:

Join us for an international expert panel discussion that will address new advances in topical retinoid treatment of acne vulgaris. A new formulation of a topical retinoid has been developed, incorporating recent developments in vehicle technology, to address shortcomings of older retinoid formulations. Acne experts from the US and Canada will discuss the clinical trial data, the value of this innovation, and how it fits into their day-to-day practice.

Professor Stuart Maddin "Dermatology 101"

Needless to say I am both honored and humbled to present the Dr. Stuart Maddin lecture at Derm Update 2021 and the anniversary of his 100th birthday (it’s actually his 101st birthday). In Stuarts book “The making of a Dermatologist: More to skin than meets the eye” I do get mentioned (honourable or dishonorable), Stuart describes me as quote “he can be prickly, he can be domineering and occasionally sometimes less than collegial.” Later down the page Stuart states “He’s punched way above his weight in terms of basic research that he’s done from that small community, compared with many, many other dermatologists in Canada who started out with greater resources at their disposal, and done bugger all.” My favourite quotes are “I’ve got great respect for him” and “I’m proud to know him”. Professor Stuart Maddin was a mentor and will always be a mentor and he was everything I wanted to be: a kind and caring Dermatologist, an outstanding research scientist, diligent entrepreneur and friend to many. Although according to Stuart, I’ve managed 3 out 4. So thanks to Stuart and all the wonderful mentors and teachers I had during my career.

I will share with you some of the clinical research and business endeavours I have had the extreme pleasure to be engaged in over the past 32 years. I will be forever grateful to my mentors Dr. Stuart Maddin, Dr. David Hawkins, Dr. David Gratton and Dr. Eugene Farber. I’m also forever indebted to supportive, caring and inspiring teachers at McGill University including Dr. Ralph Wilkinson, Bill Gerstein, Ted Arsenault, John Ellie, Brenda Moroz just to name a few. I awaken everyday with renewed vigor and abundant enthusiasm as I continue to help improve the lives of our patients through the practice of science and evidence based dermatology.

Racial/Ethnic Variations in Acne and the Role of Adjunct Skin Care

Racial/ethnic differences in the clinical presentation, sequelae, and desired treatment outcomes for acne have been reported. Notwithstanding limitations in the number, size, and methodologies of studies to date, the available data suggest that strategies to improve outcomes in acne patients with SOC include: Early initiation and maintenance of treatment regimens and careful consideration of tolerability of active ingredients, vehicles and dosing. Using pH balanced, non-irritating cleansers and non-comedogenic moisturizers to minimize irritation or dryness.

Objectives:

• Better understand the differences in acne when comparing different ethnicities;
• Discuss the challenges in treating acne in the skin of color patient;
• Review the therapeutic options in treating acne in skin of color;
• Discuss the role of moisturizers & cleansers in treating acne in skin of color;
• Explore moisturizer & cleanser ingredients offering insights into the specific role of common key ingredients in moisturizer formulations

What's new in Hidradenitis Suppurativa: From B cells to Biosimilars

Hidradenitis Suppurativa (HS) is a chronic relapsing inflammatory condition that has a major impact on patient's lives. New discoveries about the pathogenesis of HS continue to inform treatment options for these patients. The number of therapeutic options is increasing and many patients are now benefiting from immunomodulatory therapies. Clinicians need to be up to date with the most recent advancements in HS to provide the best therapeutic options for their patients.

Objectives:

• Review new findings on the pathogenesis of HS
• Explore therapeutic options for HS
• Summarize recent important clinically relevant studies

Managing Acne and Rosacea in People of Colour

Update on Cosmetic Dermatology

In this rapid fire session, we will review new additions to our cosmetic therapeutic armamentarium and up and coming products that are in development.

Latest Updates in the Management of Dry Skin-related Dermatoses

The burden of skin disease and its symptoms can significantly impact patients' quality of life. Ongoing care for patients with skin conditions can be optimized by proper adjunctive care, which can have a significant impact on patient compliance and treatment outcomes.

Objectives:

1. Discuss the importance of adjunctive therapy in the management of skin conditions.
2. Review the pathophysiology of atopic dermatitis and contact dermatitis.
3. Evaluate adjunctive therapy impact on atopic dermatitis and contact dermatitis
4. Discuss how adequate choices of adjunctive therapy can significantly impact patients' quality of life

A Sneak Peek at Bimekizumab: A Review of the Data

Dr. Ron Vender and Dr. Kerri Purdy will examine the efficacy and safety of bimekizumab in patients with moderate to severe psoriasis. At the conclusion of this session, physicians will be informed about: bimekizumab's clinical trial efficacy and safety data in patients with moderate to severe psoriasis; and Canadian investigators' first-hand experience with bimekizumab in patients with moderate to severe psoriasis.

Illumya™ is here for your patients, long SUNny days ahead

Following a presentation of tildrakizumab efficacy and safety data, participants will engage in open discussion to discuss how tildrakizumab may fill an unmet need in moderate-to-severe PsO, its place in treatment compared to IL-23 inhibitors, and best clinical practice in the management of PsO patients.

Objectives:

1. Understand & gain insights into how Canadian dermatologists currently manage patients with moderate-to-severe psoriasis;
2. Identify how tildrakizumab can fulfill an unmet need with Canadian dermatologists;
3. Share clinical experience and best practices on what outcome measures could facilitate clinical decisions in the management of patients with psoriasis.

Closing Comments

LEO Pharma Ad Board

Blexten Ad Board

CeraVe Skin of Ethnic Variations Advisory Board